Physician profile
Robert Herring
NPI 1043219165
$4,101.55
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,623 · 2020: $955 · 2021: $971 · 2022: $553.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,073.96 | 2019-2022 | |
| Gilead Sciences, INC. | $903.23 | 2019-2022 | |
| Abbvie INC. | $881.82 | 2019-2022 | |
| Janssen Biotech, INC. | $476.08 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $193.90 | 2019-2021 | |
| Redhill Biopharma INC. | $83.39 | 2020-2021 | |
| Shionogi INC | $79.70 | 2019 | |
| Merck Sharp & Dohme LLC | $77.31 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $75.43 | 2020-2022 | |
| Ucb, INC. | $72.75 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.72 | 2019-2021 | |
| Evoke Pharma, INC. | $40.35 | 2021 | |
| Pfizer INC. | $24.93 | 2019 | |
| Bausch & Lomb Americas INC. | $19.56 | 2022 | |
| Braintree Laboratories, INC. | $16.53 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $13.35 | 2019 | |
| Ferring Pharmaceuticals INC. | $11.54 | 2020 |
8 companies reported research payments only; those appear in the research section below.
Research and ownership
$1,220.84 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Herring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.